The present research work focuses on formulation, optimization and in-vivo evaluation of the orodispersible tablets of Almotriptan to achieve the desired bioavailability and give a rapid relief from the migraine headache.
Methods: The optimization was done using 22 factorial design and the formulation were subjected to several in-vitro evaluation studies. Along with stability studies for 6 months. The optimised stable formulation of Almotriptan was subjected to in-vivo studies employing animal models (rabbits) to determine the plasma concentration of the drug within required time after oral administration and the pharmacokinetic parameters such as Cmax, Tmax, AUC and others were calculated. In-vitro-in-vivo correlation was done by deconvolution using Wagner-Nelson method and the graphs were plotted to report the correlation of drugs.
Results: The almotriptan formulation F32 containing mannitol as diluent and Cross povidone 8 mg as super disintegrant has shown better release of drug i.e., 98.87% in 30 min, all the pre and post compression parameters were in limits. The optimized formulation has shown 98.27% drug release in 15 min and the same formulation was taken for in-vivo study which gave greater Cmax, Tmax and AUC values compared to marketed formulation. The in-vitro on-vivo correlation was well established with R2 value of 0.9908.
Conclusion: Almotriptan orodispersible tablets have been successfully formulated and evaluated and shows rapid release with enhanced bioavailability.
